Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis.
about
Anti-cytokine therapies for primary systemic necrotizing vasculitisWegener's granulomatosis: current and upcoming therapiesReview article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Bench-to-bedside review: Pulmonary–renal syndromes – an update for the intensivistAnti-TNF-alpha therapy and systemic vasculitis.The effect of TNFalpha blockade in complicated, refractory Kawasaki diseaseTNF superfamily: a growing saga of kidney injury modulators.Left-sided cardiac valvulitis in tristetraprolin-deficient mice: the role of tumor necrosis factor alpha.Advances in the use of biologic agents for the treatment of systemic vasculitisTumor necrosis factor-α signaling in macrophages.Immunotherapy for autoimmune and inflammatory renal diseases.Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestationsBiologic therapies: what and when?The utility of tumour necrosis factor blockade in orphan diseases.Endothelium-neutrophil interactions in ANCA-associated diseasesPrimary systemic vasculitis: treatment of difficult cases.Treatment of inflammatory dermatoses by tumour necrosis factor antagonists.EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.Biological therapies: new treatment options for ANCA-associated vasculitis?Biologic agents in systemic vasculitis.Tumor necrosis factor as a therapeutic target of rheumatologic disease.Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders.Update on the use of biologics in primary systemic vasculitides.Tumor necrosis factor biologics beyond psoriasis in dermatology.New indications for biological therapies.The role of biologics in treatment of ANCA-associated vasculitis.TNF-α blocker therapy and solid malignancy risk in ANCA-associated vasculitis.Treatment of ANCA-associated vasculitis.Biologic agents in the treatment of glomerulonephritides.Biologics for the treatment of autoimmune renal diseases.Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement.Novel strategy for the treatment of refractory vasculitis syndrome.Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects.Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-α.Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab.Retro-orbital granuloma associated with granulomatosis with polyangiitis: a series of nine cases.Biologic therapy in primary systemic vasculitis of the young.Treatment with cytapheresis for antineutrophil cytoplasmic antibody-associated renal vasculitis and its effect on anti-inflammatory factors.
P2860
Q24241555-3C8538E7-A325-43A5-A09D-C7F887BB3481Q24804964-9B53F1EF-38C6-4037-BCD0-1F0C98A1537BQ26822029-FD8B4BF1-F4F5-45EB-A250-4B2268117403Q27025692-F21B708C-FF03-47E3-BD58-2836A22750FDQ27485164-A446941D-6468-4704-9CC4-1BB1C5C43659Q27687590-76E10874-2565-4B52-B5FA-9E2F0D0E1859Q28199924-97C67078-DD14-4DED-8C3B-F97F0C2E1DB2Q30479123-FBD44CED-4401-4307-B1F5-835ADC2C570EQ33703816-F0069529-7E29-4FD9-A892-B03D0DE970BAQ34065598-94FD3791-CAEE-445D-83B1-6AC52B2EB624Q34734335-A725D8BF-E70D-40E1-9DC8-66F63B8614CAQ35144046-07AE1733-9C4E-4B6D-851F-E06B566035BAQ35579503-EDB67686-077C-40AD-8A1C-98FB792A97D6Q35637406-2AD2E1EF-6F6F-40F8-B254-6B12E3DC91BEQ35770607-0121EC64-796A-4CCD-B481-D082F4D181D8Q35915996-7966A299-EA61-42CA-9A95-0459F4F3E79EQ36200937-3A1BCE4D-EBE6-4BAF-98BD-D184F035EA13Q36458145-C1059296-4FFD-49DB-A099-95248D49EBBFQ36633460-B59EF740-BA61-4C36-885B-B2780032B775Q36684589-8366BC5A-EDA9-4074-9068-6F3AC4389532Q36764935-307D25CC-4122-4CB8-8FD9-52DD06319017Q36934322-BB0F498B-E547-4FCF-A747-5B461D49B9A0Q37008829-FA06F084-A848-4B2C-8E49-E814F7ED0FABQ37754686-0E71A4C8-F218-4887-A1EA-9CE290C7A030Q37754811-12B6B80E-E212-4527-8459-16E116CF37BDQ37886194-3D68369D-D7F4-49CC-89D0-742BA340E038Q37947157-599ADEE2-7842-4C3C-A15F-02326014A7AEQ37950904-06055C39-537E-4DAF-8004-1C1A60C53443Q38041477-9049D85C-0614-4475-A304-C9627FBA910BQ38159916-CABE673A-FFC1-45CB-8AD4-3AEC59797BFAQ38514894-EC4DF374-6BB9-4EB0-AA85-A7D172647F2CQ38763327-1044B83A-3905-4CF3-A4AD-75B72B6D8BDAQ38946711-A6CE4779-5144-42FB-A9F9-D13174155D75Q40066118-DA12103D-EA82-454E-B03E-A7A60028F518Q42844981-F2761829-1088-47BE-99B5-D446262CB529Q42948710-A6A5F806-0098-42BB-89E4-ED8575D02F78Q42955954-1F44250B-782D-4417-9C54-80353E3E5B5AQ44641551-8E559ED2-38C2-4AF8-BC13-C0173152FD39Q45964920-79DE0B47-8E43-4EA2-9869-F19263F91AE5Q46631789-695E6DE4-35B8-416E-A35B-38679C3F6A85
P2860
Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Effectiveness of TNF-alpha blo ...... tory Wegener's granulomatosis.
@en
Effectiveness of TNF-alpha blo ...... tory Wegener's granulomatosis.
@nl
type
label
Effectiveness of TNF-alpha blo ...... tory Wegener's granulomatosis.
@en
Effectiveness of TNF-alpha blo ...... tory Wegener's granulomatosis.
@nl
prefLabel
Effectiveness of TNF-alpha blo ...... tory Wegener's granulomatosis.
@en
Effectiveness of TNF-alpha blo ...... tory Wegener's granulomatosis.
@nl
P2093
P356
P1433
P1476
Effectiveness of TNF-alpha blo ...... tory Wegener's granulomatosis.
@en
P2093
Lamprecht P
Lilienthal T
Voswinkel J
P304
P356
10.1093/RHEUMATOLOGY/41.11.1303
P577
2002-11-01T00:00:00Z